Welcome to LookChem.com Sign In|Join Free
  • or
O-(paclitaxel-2'-yl) 3-maleimidopropionate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

254893-84-0

Post Buying Request

254893-84-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

254893-84-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 254893-84-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,4,8,9 and 3 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 254893-84:
(8*2)+(7*5)+(6*4)+(5*8)+(4*9)+(3*3)+(2*8)+(1*4)=180
180 % 10 = 0
So 254893-84-0 is a valid CAS Registry Number.

254893-84-0Downstream Products

254893-84-0Relevant academic research and scientific papers

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2-Expressing Breast Cancers

Jang, Joo Hee,Han, Sang Jin,Kim, Jung Young,Kim, Kwang Il,Lee, Kyo Chul,Kang, Chi Soo

, p. 451 - 456 (2019)

The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)-chelated 89Zr have been reported. These comounds have potential applications against HER2 receptor positive bre

Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ6

Li, Shunzi,Gray, Bethany Powell,McGuire, Michael J.,Brown, Kathlynn C.

, p. 5480 - 5489 (2011)

The integrin αvβ6 is an emergent biomarker for non-small cell lung cancer (NSCLC) as well as other carcinomas. We previously developed a tetrameric peptide, referred to as H2009.1, which binds αvβ6 and displays

HIGH AFFINITY CXCR4 SELECTIVE BINDING CONJUGATE AND METHOD FOR USING THE SAME

-

Paragraph 0075, (2019/04/09)

This disclosure provides a peptide conjugate (PC) that can be used for targeted drug delivery, imaging a patient, or diagnosing a subject for a condition associated with overexpression and/or upregulation of CXCR4, including cancers, HIV infection, and im

CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION

-

Paragraph 1189-1191, (2015/11/18)

The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin

Wang, Shudong,Zhelev, Nikolai Z.,Duff, Susan,Fischer, Peter M.

, p. 2628 - 2631 (2007/10/03)

Synthesis of paclitaxel-penetratin (pAntp) constructs, in which the 2′- or 7-position of paclitaxel was used as the attachment site for linker connecting the drug and peptide moieties, is described. Paclitaxel-2′-pAntp[43-58]-NH2 3b and paclita

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 254893-84-0